Weicheng Pharmaceuticals exceeded the target by completing a Series A funding of $54 million.

Recently, Weicheng Pharmaceuticals Co., Ltd. announced the completion of a $54 million oversubscribed Series A financing. Sequoia Capital China led the round. The funds raised in this round will be mainly used for the iterative optimization of the company's core liver extracellular delivery technology platform, the clinical advancement of multiple pipelines, and team expansion and the establishment of a global research and development network.